Bioiberica keeps within group “A” of Plan Profarma, thereby certifying their compromise with R&D and production in Spain

Barcelona, April 28th, 2015. The PROFARMA Plan of the Ministry of Industry has rated given the “good” rating to Bioiberica, thus giving recognition to its efforts and commitment to R&D in Spain. Our company keeps, for one more year, within the A group, which includes those firms carrying out significant research activity at their own production or R&D Center. 

Bioiberica is a biotech firm specializing in the research, development, production and commercialization of bio-molecules for the pharmaceutical, veterinary and agrochemical industries. In the human healthcare field, we are a leading firm in heparin and osteoarthritis, area in which we are focused on innovation. “At this stage we have projects for the development of biomarkers that could help us to detect osteoarthritis before it manifests itself. We are also researching in cell therapy. Furthermore, we are participating in international observational trials that use Big Data to gain better information about the dimensions and quality of life of patients suffering from that disease”, declared Dr. Josep Vergés, clinical pharmacologists and medical and scientific director at Bioiberica. 

The PROFARMA Plan is a joint initiative of the following ministries: Industry, Tourism and Trade; Healthcare and Social Policies; Science and Innovation. Its aim is to increase the competitiveness of the pharmaceutical industry in Spain through the modernization of its sector and boosting those sectors giving greater added value.